Aquestive Therapeutics, Inc. (AQST)
Market Cap | 274.45M |
Revenue (ttm) | 58.90M |
Net Income (ttm) | -35.19M |
Shares Out | 91.18M |
EPS (ttm) | -0.44 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,019,253 |
Open | 3.120 |
Previous Close | 3.060 |
Day's Range | 3.010 - 3.150 |
52-Week Range | 2.240 - 6.230 |
Beta | 2.66 |
Analysts | Strong Buy |
Price Target | 10.38 (+244.85%) |
Earnings Date | Mar 5, 2025 |
About AQST
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of... [Read more]
Financial Performance
In 2023, Aquestive Therapeutics's revenue was $50.58 million, an increase of 6.09% compared to the previous year's $47.68 million. Losses were -$7.87 million, -85.54% less than in 2022.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for AQST stock is "Strong Buy." The 12-month stock price forecast is $10.38, which is an increase of 244.85% from the latest price.
News

Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting
WARREN, N.J., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement...

Aquestive Therapeutics: Five Foci For 2025
Aquestive Therapeutics' Anaphylm is nearing FDA approval, potentially disrupting the U.S. anaphylaxis market dominated by EpiPen, with peak sales estimated at $300–400M. AQST-108, a topical epinephrin...

Undercovered Dozen: Asbury Automotive, Globalstar, Northland Power, Aquestive Therapeutics +
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering fresh investment ideas and sparking community discussions on their potential. Xometry's AI-driven procurement software in ...

Aquestive Therapeutics, Inc. (AQST) Q3 2024 Earnings Call Transcript
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q3 2024 Earnings Call Transcript November 5, 2024 8:00 AM ET Company Participants Bennett Watson - IR, ICR Westwicke IR Dan Barber - CEO Ernie Toth - CFO Sh...

Aquestive: Rare Opportunity With Dual Platform Strategy
Aquestive Therapeutics specializes in innovative film-based medicines and epinephrine products & delivery. The company's PharmFilm and Adrenaverse platforms offer unique competitive advantages, making...

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
WARREN, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement ...

Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
WARREN, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvemen...

Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
WARREN, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvemen...

Aquestive Therapeutics: Bullish Roadmap After Q2 Earnings
Aquestive Therapeutics Q2 earnings report showed significant beats in EPS and revenue, with a 52% year-over-year revenue increase. The company reported improved operational efficiency and profitabilit...

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement...

Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025
Aquestive Therapeutics shares surged 137.29% (YoY) after FDA approval of rival company ARS Pharmaceutical's "epinephrine nasal spray" Neffy. Market optimism surrounds AQST's robust R&D pipeline, with ...

Aquestive Therapeutics Inc. (AQST) Q2 2024 Earnings Call Transcript
Aquestive Therapeutics Inc. (NASDAQ:AQST) Q2 2024 Earnings Conference Call August 7, 2024 8:00 AM ET Company Participants Bennett Watson - ICR Westwicke Investor Relations Dan Barber - Chief Executiv...

Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
WARREN, N.J., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement ...

Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study
WARREN, N.J., July 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement...

Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET
WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement...

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement...

Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
WARREN, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement...

Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
WARREN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through inno...

Aquestive Therapeutics, Inc. (AQST) Q1 2024 Earnings Call Transcript
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Bennett Watson – ICR Westwicke Investor Relations Dan Barber – Chief Executive ...

Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
WARREN, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innov...

Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvemen...

Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024
Aquestive Therapeutics has achieved positive Phase III data for their Anaphylm epinephrine sublingual film, showing comparable efficacy to auto-injectors.

Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
WARREN, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvemen...

Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvemen...

Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvemen...